Orthofix International NV shares plummeted 5.01% during Tuesday's intraday trading session, as the medical device maker's disappointing fourth-quarter earnings report weighed heavily on investor sentiment.
For the quarter ended December 2024, Orthofix reported earnings per share of $0.02, missing the consensus estimate of $0.06 per share. However, the company's revenue of $215.66 million surpassed expectations of $212.63 million. The earnings miss was a major disappointment for investors, despite the revenue beat.
Looking ahead, Orthofix expects full-year revenue for 2025 to range between $818 million and $826 million. Investors will closely monitor the company's performance and guidance in the coming quarters to assess its ability to regain profitability and deliver consistent earnings growth.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。